Theriva Biologics Stock Surges 73.6% on AACR Data

Theriva Biologics shares jumped 73.6% on April 21, 2026 after releasing Phase 2b VIRAGE trial data at AACR meeting.
VCN-01 combined with gemcitabine/nab-paclitaxel showed improved overall survival and progression‑free survival versus chemotherapy alone, including liver‑metastasis subgroup.
A second VCN-01 dose further increased survival benefits, and the company secured FDA and EMA alignment for a pivotal Phase 3 trial.
Theriva plans to test multiple and extended VCN-01 dosing, citing immune‑mediated mechanism indicated by tumor response and biomarker data.